As the market moves rapidly toward value-based care, one cardiology physician describes how working with New Century Health gave his practice the confidence and support to succeed in an advanced alternative payment model.
Other content in this Stream
Panel Discussion: Oncology Care Reimagined
Health plan clinical leaders joined us for an insightful discussion on the path toward high-value cancer care.
Episode 7: Underuse In Cardiology Is Under-Appreciated. How Do We Change That?
Learn why underuse is a major problem and how we might tackle it
Home-based chemotherapy infusions may offer convenience but also raise a host of questions.
Shouldering the Burden and Financial Toxicity of Part D Cancer Drugs
Discussing drug costs should be a core tenet of shared decision-making.
New Century Health Parent Company Elects Dr. Tunde Sotunde To Board Of Directors
Sotunde is president and CEO of Blue Cross and Blue Shield of North Carolina.
New Century Health to Support Health New England With Comprehensive Advance Care Planning Services
Partnership will empower members with serious illness to articulate and advocate for the care they want.
Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.
GDMT, or guideline-directed medical therapy, means taking the right medication at the optimal doses to treat cardiovascular problems. Yet these medications are chronically underused.
Every day, cardiologists make decisions about what is the most appropriate test, therapy, or procedure for their patients. But then COVID-19 came along. Have the rules of the game changed?
Our CMO speaks with Managed Care Executive about the promise and perils of genomic testing.
Health Systems' Rare Rejection of Alzheimer's Drug Sparks Questions About FDA Approvals
Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.
Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.
Evolent Health, Parent Company of New Century Health, Announces Agreement to Acquire Vital Decisions
The addition of Vital Decisions’ specialized patient engagement services expected to position New Century Health to accelerate growth, improve patient care quality and increase margins.
Hitting the Brakes on Fast-Tracked Drugs
The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.
Top Takeaways from the 2021 ASCO Annual Meeting
Our chief medical officer highlights noteworthy research and results from clinical oncology's premier event.
New Century Health, a national leader in specialty care management, is proud to provide comprehensive oncology specialty management services to Neighborhood Health Plan of Rhode Island.
New Century Health CMO, Dr. Andrew Hertler, shares his thoughts on the recent FDA meetings to review the merits of approved cancer drugs.
Our CMO Dr. Andrew Hertler speaks with HFMA about the role of telehealth in oncology care today.
Traditional UM Programs Can't Move the Needle in Cardiology Care. Here's What Does.
Senior Medical Director Fernando Villacian lays out the key tenets of an effective cardiovascular management program.
In this podcast series we explore the trends and forces behind the two leading causes of death in the United States: cancer and heart disease.